US-based pharmaceutical firm Pfizer has started construction on its new research and development (R&D) and process development facility in Missouri, US.
The facility will provide about 295,000 sq ft of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. It will bring together the company’s 450 current employees working in the St Louis area while it will create 80 positions to support research at the site.
The new campus will include a floor plan which offers flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate.
CRG is offering design-build management services, while Clayco is acting as the design-builder. All architecture, landscape design, engineering, interior and lab/process design will be provided by Forum and Ewing Cole.
Construction of the new campus is anticipated to be completed by mid-2019.
Pfizer senior vice president of BioTherapeutics Pharmaceutical Sciences John Ludwig said: “We’ve been proud to call Missouri home since 2002. During this time, we’ve benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the State, St. Louis County, and the St. Louis Economic Development Partnership.
“All of these were important factors as we sought a new home where we could continue to evolve our business over the coming years.”